{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:57:08Z","timestamp":1782946628704,"version":"3.54.5"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Head and neck squamous cell carcinoma (HNSCC) originates from the squamous epithelium of the oral cavity, oropharynx, larynx, and hypopharynx. HNSCC in the oral cavity and larynx is strongly associated with tobacco smoking and alcohol consumption, while oropharyngeal cancer is increasingly attributed to infection by human papillomavirus (HPV), particularly HPV-16. The tumor microenvironment (TME) is a complex network of cancer cells, immune cells, stromal cells, surrounding blood vessels, and signaling molecules, and plays a critical role in tumor cell survival, invasion, and recurrence. Therefore, it is critical to elucidate the molecular basis of the interaction between tumor cells and the TME in order to develop innovative anti-cancer therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fmed.2023.1257898","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T06:07:31Z","timestamp":1693462051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeted therapy for head and neck squamous cell carcinoma microenvironment"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhaomeng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/cas.14784","article-title":"Personalized cancer vaccination in head and neck cancer","volume":"112","author":"Shibata","year":"2021","journal-title":"Cancer Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1200\/JCO.2006.07.1829","article-title":"Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers","volume":"24","author":"Gillison","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000477127","article-title":"Epidemiology and molecular biology of head and neck cancer","volume":"40","author":"Jou","year":"2017","journal-title":"Oncol Res Treat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4248\/IJOS11068","article-title":"A review of clinical and histological parameters associated with contralateral neck metastases in oral squamous cell carcinoma","volume":"3","author":"Fan","year":"2011","journal-title":"Int J Oral Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fcell.2019.00052","article-title":"Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy","volume":"7","author":"Canning","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","article-title":"New horizons in tumor microenvironment biology: challenges and opportunities","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the tme to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/CAD.0b013e328337160e","article-title":"Treatment approaches to nasopharyngeal carcinoma: a review","volume":"21","author":"Caponigro","year":"2010","journal-title":"Anti-Cancer Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-020-00340-2","article-title":"Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma","volume":"5","author":"Kang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.canlet.2017.10.037","article-title":"Metabolic changes in tumor cells and tumor-associated macrophages: a mutual relationship","volume":"413","author":"Netea-Maier","year":"2018","journal-title":"Cancer Lett"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"773028","DOI":"10.3389\/fonc.2021.773028","article-title":"Metabolic reprogramming of thyroid cancer cells and crosstalk in their microenvironment","volume":"11","author":"Bao","year":"2021","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: a great barrier in the age of cancer immunotherapy","author":"El-Sayes","year":"2021","journal-title":"Cancers"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.3390\/ijms19103028","article-title":"Role of extracellular matrix in development and cancer progression","author":"Walker","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12943-022-01670-1","article-title":"Targeting the tumor stroma for cancer therapy","volume":"21","author":"Xu","year":"2022","journal-title":"Mol Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.3390\/ijms22105283","article-title":"Influence of tumor microenvironment and fibroblast population plasticity on melanoma growth, therapy resistance and immunoescape","author":"Romano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.3390\/cancers14174172","article-title":"Thyroid cancer and fibroblasts","author":"Avagliano","year":"2022","journal-title":"Cancers"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","article-title":"Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.3390\/cancers12102785","article-title":"Angiotensin inhibition, tgf-beta and emt in cancer","author":"Pallasch","year":"2020","journal-title":"Cancers"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"111182","DOI":"10.1016\/j.biopha.2020.111182","article-title":"Halofuginone regulates keloid fibroblast fibrotic response to tgf-beta induction","volume":"135","author":"Marty","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1056337","DOI":"10.3389\/fphar.2022.1056337","article-title":"Halofuginone inhibits tumor migration and invasion by affecting cancer-associated fibroblasts in oral squamous cell carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e000664","DOI":"10.1136\/jitc-2020-000664","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting tgf-beta and pd-l1, in advanced squamous cell carcinoma of the head and neck: results from a phase i cohort","author":"Cho","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40164-020-00192-0","article-title":"Cd44 as a tumor biomarker and therapeutic target","volume":"9","author":"Xu","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"ref30","first-page":"3046","article-title":"Safety and biodistribution of 99mtechnetium-labeled anti-cd44v6 monoclonal antibody biwa 1 in head and neck cancer patients","volume":"6","author":"Stroomer","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2005.06.038","article-title":"Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy","volume":"77","author":"Nordsmark","year":"2005","journal-title":"Radiother Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"Hockel","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/1097-0142(19930401)71:7<2319::AID-CNCR2820710724>3.0.CO;2-C","article-title":"Oxygenation of head and neck tumors","volume":"71","author":"Lartigau","year":"1993","journal-title":"Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.4161\/cbt.8.21.9988","article-title":"Modulating the tumor microenvironment to increase radiation responsiveness","volume":"8","author":"Karar","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumor microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogene"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semradonc.2004.04.008","article-title":"Tumor microenvironmental physiology and its implications for radiation oncology","volume":"14","author":"Vaupel","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"20180047","DOI":"10.1259\/bjr.20180047","article-title":"Hpv, hypoxia and radiation response in head and neck cancer","volume":"92","author":"Gottgens","year":"2019","journal-title":"Br J Radiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.biocel.2004.08.012","article-title":"Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators","volume":"37","author":"Dery","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1359-6446(04)03202-7","article-title":"The hif pathway as a therapeutic target","volume":"9","author":"Hewitson","year":"2004","journal-title":"Drug Discov Today"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1634\/theoncologist.9-90005-10","article-title":"The role of hypoxia-induced factors in tumor progression","volume":"9","author":"Vaupel","year":"2004","journal-title":"Oncologist"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1517\/14728222.2014.925447","article-title":"Osteopontin as a therapeutic target for cancer","volume":"18","author":"Bandopadhyay","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","article-title":"The role of carbonic anhydrase ix in cancer development: links to hypoxia, acidosis, and beyond","volume":"38","author":"Pastorekova","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.critrevonc.2016.05.005","article-title":"Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck","volume":"103","author":"Curtis","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.oraloncology.2018.03.004","article-title":"Hypoxia induced emt: a review on the mechanism of tumor progression and metastasis in oscc","volume":"80","author":"Joseph","year":"2018","journal-title":"Oral Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-06-2046","article-title":"Phase i\/ii study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer","volume":"13","author":"Dreicer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.18632\/oncotarget.2163","article-title":"Targeting hypoxia-inducible factor-1alpha (hif-1alpha) in combination with antiangiogenic therapy: a phase i trial of bortezomib plus bevacizumab","volume":"5","author":"Falchook","year":"2014","journal-title":"Oncotarget"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-11-0682","article-title":"Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors","volume":"17","author":"Kummar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A phase 1 study of slc-0111, a novel inhibitor of carbonic anhydrase ix, in patients with advanced solid tumors","volume":"43","author":"McDonald","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature17039","article-title":"Reparative inflammation takes charge of tissue regeneration","volume":"529","author":"Karin","year":"2016","journal-title":"Nature"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/bs.acr.2015.04.014","article-title":"Tumor-elicited inflammation and colorectal cancer","volume":"128","author":"Wang","year":"2015","journal-title":"Adv Cancer Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.oraloncology.2009.03.016","article-title":"An overview on the expression of cyclooxygenase-2 in tumors of the head and neck","volume":"45","author":"Mendes","year":"2009","journal-title":"Oral Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/hed.20830","article-title":"Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer","volume":"30","author":"Hamakawa","year":"2008","journal-title":"Head Neck"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10555-018-9746-9","article-title":"Eicosanoids and hb-egf\/egfr in cancer","volume":"37","author":"Yang","year":"2018","journal-title":"Cancer Metastasis Rev"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s12253-015-9940-9","article-title":"Cyclooxygenase-2--an imperative prognostic biomarker in oral squamous cell carcinoma--an immunohistochemical study","volume":"21","author":"Byatnal","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1734-1140(09)70004-0","article-title":"Icam-1 signaling in endothelial cells","volume":"61","author":"Lawson","year":"2009","journal-title":"Pharmacol Rep"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"29808","DOI":"10.1074\/jbc.M110.108183","article-title":"Prostaglandin e2\/ep1 signaling pathway enhances intercellular adhesion molecule 1 (icam-1) expression and cell motility in oral cancer cells","volume":"285","author":"Yang","year":"2010","journal-title":"J Biol Chem"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.seminoncol.2004.03.040","article-title":"Multiple roles of cox-2 in tumor angiogenesis: a target for antiangiogenic therapy","volume":"31","author":"Gately","year":"2004","journal-title":"Semin Oncol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.oooo.2013.12.410","article-title":"Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-c and lymph node metastasis in human oral tongue cancer","volume":"117","author":"Morita","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e173641","DOI":"10.1371\/journal.pone.0173641","article-title":"Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hed.10108","article-title":"Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer","volume":"24","author":"Lin","year":"2002","journal-title":"Head Neck"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/cancers10100348","article-title":"Role of cox-2\/pge2 mediated inflammation in oral squamous cell carcinoma","author":"Nasry","year":"2018","journal-title":"Cancers"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.apsb.2022.01.002","article-title":"Recent development on cox-2 inhibitors as promising anti-inflammatory agents: the past 10 years","volume":"12","author":"Ju","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1200\/JCO.2005.09.112","article-title":"Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention","volume":"23","author":"Dannenberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S0016-5085(03)01061-8","article-title":"The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases","volume":"125","author":"Fenwick","year":"2003","journal-title":"Gastroenterology"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase ii nonrandomized study of the efficacy and safety of cox-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J Mol Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrd3930","article-title":"Clinical targeting of the tnf and tnfr superfamilies","volume":"12","author":"Croft","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2353\/ajpath.2010.091218","article-title":"Tumor necrosis factor receptor expression and signaling in renal cell carcinoma","volume":"177","author":"Al-Lamki","year":"2010","journal-title":"Am J Pathol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/cancers13030564","article-title":"Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy","author":"Mercogliano","year":"2021","journal-title":"Cancers"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1038\/onc.2016.112","article-title":"Tnf-alpha modulates genome-wide redistribution of deltanp63alpha\/tap73 and nf-kappab crel interactive binding on tp53 and ap-1 motifs to promote an oncogenic gene program in squamous cancer","volume":"35","author":"Si","year":"2016","journal-title":"Oncogene"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.26355\/eurrev_201811_16395","article-title":"Mir-21 regulates proliferation and apoptosis of oral cancer cells through tnf-alpha","volume":"22","author":"Qiu","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41598-021-81500-4","article-title":"Tnfalpha promotes oral cancer growth, pain, and schwann cell activation","volume":"11","author":"Salvo","year":"2021","journal-title":"Sci Rep"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12957-020-01958-w","article-title":"Role of mmp-9 in epithelial-mesenchymal transition of thyroid cancer","volume":"18","author":"Li","year":"2020","journal-title":"World J Surg Oncol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/MLG.0b013e318174e09b","article-title":"Tnf-alpha drives matrix metalloproteinase-9 in squamous oral carcinogenesis","volume":"118","author":"Hohberger","year":"2008","journal-title":"Laryngoscope"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.7150\/jca.55580","article-title":"Increased tumor-infiltrating plasmacytoid dendritic cells promote cancer cell proliferation and invasion via tnf-alpha\/nf-kappab\/cxcr-4 pathway in oral squamous cell carcinoma","volume":"12","author":"Han","year":"2021","journal-title":"J Cancer"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1007\/s13277-015-4418-7","article-title":"Tnf-alpha increases the membrane expression of the chemokine receptor ccr6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer","volume":"37","author":"Coperchini","year":"2016","journal-title":"Tumour Biol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","article-title":"Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase ii trials of infliximab at standard and high dose","volume":"25","author":"Harrison","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1158\/1078-0432.CCR-04-0730","article-title":"A phase ii study of etanercept (enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer","volume":"10","author":"Madhusudan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2017.04.005","article-title":"Tumor promoting role of anti-tumor macrophages in tumor microenvironment","volume":"316","author":"Goswami","year":"2017","journal-title":"Cell Immunol"},{"key":"ref84","first-page":"376","article-title":"Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer","volume":"4","author":"Quatromoni","year":"2012","journal-title":"Am J Transl Res"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"14611","DOI":"10.1038\/s41598-019-51149-1","article-title":"Cd206(+) tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via egf production","volume":"9","author":"Haque","year":"2019","journal-title":"Sci Rep"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4103\/aam.aam_8_17","article-title":"Tumor-associated macrophages, angiogenesis, and tumor cell migration in oral squamous cell carcinoma","volume":"16","author":"Udeabor","year":"2017","journal-title":"Ann Afr Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"118798","DOI":"10.1016\/j.lfs.2020.118798","article-title":"Tumor-regulated macrophage type 2 differentiation promotes immunosuppression in laryngeal squamous cell carcinoma","volume":"267","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"87037","DOI":"10.18632\/oncotarget.13523","article-title":"Ccl2\/egf positive feedback loop between cancer cells and macrophages promotes cell migration and invasion in head and neck squamous cell carcinoma","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (cnto 888), a human monoclonal antibody against cc-chemokine ligand 2 (ccl2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Investig New Drugs"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with ccr2 inhibition in combination with folfirinox in patients with borderline resectable and locally advanced pancreatic cancer: a single-Centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (csf-1) and antagonists of csf-1 receptor (csf-1r) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase i study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive m2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann Oncol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1158\/1078-0432.CCR-16-3261","article-title":"First-in-human study of amg 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors","volume":"23","author":"Papadopoulos","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (enliven): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clcc.2022.11.003","article-title":"Rocket: phase ii randomized, active-controlled, multicenter trial to assess the safety and efficacy of rrx-001 + irinotecan vs. single-agent regorafenib in third\/fourth line colorectal cancer","volume":"22","author":"Reid","year":"2023","journal-title":"Clin Colorectal Cancer"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nri1498","article-title":"Mechanisms and functional significance of tumour-induced dendritic-cell defects","volume":"4","author":"Gabrilovich","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s41467-018-03966-7","article-title":"Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via cxcr2 ligand upregulation","volume":"9","author":"Taki","year":"2018","journal-title":"Nat Commun"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of cd8+ t cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.it.2015.02.005","article-title":"Intertwined regulation of angiogenesis and immunity by myeloid cells","volume":"36","author":"Rivera","year":"2015","journal-title":"Trends Immunol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/hed.24595","article-title":"Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck","volume":"39","author":"Chen","year":"2017","journal-title":"Head Neck"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"e229089","DOI":"10.1371\/journal.pone.0229089","article-title":"Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma","volume":"15","author":"Pang","year":"2020","journal-title":"PLoS One"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/thy.2015.0289","article-title":"Circulating myeloid-derived suppressor cells predict differentiated thyroid cancer diagnosis and extent","volume":"26","author":"Angell","year":"2016","journal-title":"Thyroid"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"e1226719","DOI":"10.1080\/2162402X.2016.1226719","article-title":"Cd24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells","volume":"5","author":"Fugle","year":"2016","journal-title":"Onco Targets Ther"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/ijc.32781","article-title":"Stat1 inhibits t-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma","volume":"146","author":"Ryan","year":"2020","journal-title":"Int J Cancer"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","article-title":"Tadalafil reduces myeloid-derived suppressor cells and regulatory t cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Weed","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","article-title":"Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with ipilimumab","volume":"63","author":"Tobin","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-09-3272","article-title":"Anti-inflammatory triterpenoid blocks immune suppressive function of mdscs and improves immune response in cancer","volume":"16","author":"Nagaraj","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2147\/DDDT.S68872","article-title":"Bardoxolone methyl (cddo-me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties","volume":"8","author":"Wang","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"e1431082","DOI":"10.1080\/2162402X.2018.1431082","article-title":"Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of natural killer cell cytotoxicity","volume":"7","author":"Tai","year":"2018","journal-title":"Onco Targets Ther"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with pde5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cells"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.2353\/ajpath.2009.090202","article-title":"Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors","volume":"175","author":"Akino","year":"2009","journal-title":"Am J Pathol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/0008-5472.CAN-15-2998","article-title":"Endothelial side population cells contribute to tumor angiogenesis and antiangiogenic drug resistance","volume":"76","author":"Naito","year":"2016","journal-title":"Cancer Res"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of vegf and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fonc.2018.00367","article-title":"The tumor vascular endothelium as decision maker in cancer therapy","volume":"8","author":"Klein","year":"2018","journal-title":"Front Oncol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1080\/21655979.2022.2033013","article-title":"Procyanidin b2 inhibits angiogenesis and cell growth in oral squamous cell carcinoma cells through the vascular endothelial growth factor (vegf)\/vegf receptor 2 (vegfr2) pathway","volume":"13","author":"Sun","year":"2022","journal-title":"Bioengineered"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7150\/ijbs.66506","article-title":"Exosomal lbh inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating vegfa signaling","volume":"18","author":"Wu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.7150\/jca.46429","article-title":"Vegf promotes migration and invasion by regulating emt and mmps in nasopharyngeal carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"J Cancer"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/ijgc-2021-002434","article-title":"Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase iv Mito-16a\/mango-ov2a study","volume":"31","author":"Daniele","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","article-title":"Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the reality randomized clinical trial","volume":"8","author":"Lin","year":"2022","journal-title":"JAMA Oncol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.esmoop.2021.100079","article-title":"Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase i study","volume":"6","author":"Cascone","year":"2021","journal-title":"Esmo Open"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1200\/JCO.2017.72.7297","article-title":"Phase iii, randomized, placebo-controlled, double-blind trial of motesanib (amg-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Kubota","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.07.029","article-title":"Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: final results of the randomised, multicenter, open-label phase ii trial pazothyr","volume":"157","author":"de la Fouchardiere","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.12.009","article-title":"Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: long-term efficacy and safety from a phase ib trial","volume":"145","author":"Atkins","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.1038\/s41467-022-35133-4","article-title":"A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma","volume":"13","author":"Xia","year":"2022","journal-title":"Nat Commun"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase ii study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (hope)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 cosmic-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1002\/cncr.32964","article-title":"A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer","volume":"126","author":"Kim","year":"2020","journal-title":"Cancer"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature13305","article-title":"Sox2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma","volume":"511","author":"Boumahdi","year":"2014","journal-title":"Nature"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrc3368","article-title":"Cancer stem cell definitions and terminology: the devil is in the details","volume":"12","author":"Valent","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.semcancer.2018.06.001","article-title":"Reactive oxygen species in cancer stem cells of head and neck squamous cancer","volume":"53","author":"Qian","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"djw189","DOI":"10.1093\/jnci\/djw189","article-title":"Regulation of head and neck squamous cancer stem cells by pi3k and sox2","author":"Keysar","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"1084926","DOI":"10.3389\/fimmu.2023.1084926","article-title":"Effects of chemotherapy and immunotherapy on microbial diversity in tme and engineered bacterial-mediated tumor therapy","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/carcin\/bgac063","article-title":"Intratumoral microbiota: new frontiers in tumor immunity","volume":"43","author":"Zhang","year":"2022","journal-title":"Carcinogenesis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1257898\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T06:07:38Z","timestamp":1693462058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1257898\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":138,"alternative-id":["10.3389\/fmed.2023.1257898"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1257898","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"article-number":"1257898"}}